The tweet was deleted by the author.
But we saved everything 🙂.
Biomea Fusion has announced positive 52 week results from its Phase 2 COVALENT 112 trial, which is evaluating icovamenib in patients with type 1 diabetes.
The company reported a 52 percent increase in mean C peptide area under the curve at week 12, with the effect largely maintained through week 52, experiencing only a 7 percent decline after the initial 12 weeks of dosing. These findings suggest sustained efficacy of icovamenib over a full year. More details on the clinical implications and next development steps are awaited.
Biomea Fusion previously outlined key milestones for icovamenib, with COVALENT trial data projected for 2026 in its development timeline. The company has also reported that diabetes remains poorly controlled in many patients despite standard therapies. These background factors provide context for the latest 52-week efficacy results.